# Blocking Extracellular Galectin-3 in Patients With Osteoarthritis

> **NCT02800629** · PHASE3 · UNKNOWN · sponsor: **Massachusetts General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Osteoarthritis

## Interventions

- **DIETARY_SUPPLEMENT:** Modified Citrus Pectin
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT02800629
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2018-05
- **Final completion:** 2018-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02800629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02800629, "Blocking Extracellular Galectin-3 in Patients With Osteoarthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02800629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*